Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Clinical trial NCT06698965 · RECRUITING
Trial details
- NCT number
- NCT06698965
- Sponsor
- Shanghai Chest Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-13
- Primary completion
- 2029-10-31
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.